Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA.
Analysis Group, Inc., Montreal, QC, H3B 0G7, Canada.
Future Oncol. 2021 Aug;17(22):2907-2921. doi: 10.2217/fon-2021-0153. Epub 2021 Apr 28.
To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for , , , and gene alterations were assessed. Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.
评估在 PARP 抑制剂获批前接受转移性去势抵抗性前列腺癌（mCRPC）治疗的患者进行同源重组修复基因突变基因检测的模式。在肿瘤电子病历数据库中选择 mCRPC 患者。评估检测、、、和基因改变的模式和预测因素。在 5213 例 mCRPC 患者中，有 674 例（13%）有记录的基因检测。接受检测的患者人数从 2013 年的 1 例增加到 2018 年的 313 例（分别为 3161 例和 3010 例临床活跃患者）。在学术肿瘤中心（而不是社区中心）接受治疗强烈预测基因检测（风险比=2.41）。PARP 抑制剂获批前基因检测的使用和获得并不理想。
